Pepro Tech
Originally published online as doi:10.1189/jlb.0608390 on November 6, 2008

Published online before print November 6, 2008
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
jlb.0608390v1
85/2/322    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, H.
Right arrow Articles by Kaminski, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, H.
Right arrow Articles by Kaminski, N. E.
(Journal of Leukocyte Biology. 2009;85:322-329.)
© 2009 Society for Leukocyte Biology

Suppression of T cell costimulator ICOS by {Delta}9-tetrahydrocannabinol

Haitian Lu, Barbara L. F. Kaplan, Thitirat Ngaotepprutaram and Norbert E. Kaminski1

Department of Pharmacology and Toxicology and Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA

1 Correspondence: Department of Pharmacology and Toxicology, Center for Integrative Toxicology, 315 National Food Safety and Toxicology Building, East Lansing, MI, 48824-1317, USA. E-mail: kamins11{at}msu.edu

ABSTRACT

Inducible costimulator (ICOS), a prototypic T cell costimulator, is induced on activated T cells. ICOS regulates T cell activation and Th cell differentiation and is principally involved in humoral immune responses. Previous work showed that T cell accessory function is modulated by the plant-derived cannabinoid, delta-9-tetrahydrocannabinol ({Delta}9-THC). In light of an emerging role by ICOS in T cell-mediated immunity, the objective of this study was to investigate the effect of {Delta}9-THC on ICOS in activated mouse T cells. Induction of ICOS mRNA levels by phorbol ester (PMA) plus ionomycin (Io) activation in mouse splenocytes was attenuated by {Delta}9-THC in a concentration-related manner. Similar results were obtained in the mouse T cell line, EL4.IL-2. Anti-CD3/CD28 induced ICOS expression on CD4+ splenic T cells, which was suppressed by {Delta}9-THC in a time- and concentration-related manner. The PMA/Io-induced icos promoter luciferase reporter activity was also down-regulated by {Delta}9-THC, suggesting that the suppression of ICOS expression by {Delta}9-THC occurs at the transcriptional level. Moreover, transcriptional activation of the NFAT was also down-regulated by {Delta}9-THC as shown by a NFAT luciferase reporter assay, which is consistent with a putative role of NFAT in regulating ICOS expression. Collectively, {Delta}9-THC suppresses ICOS expression in activated T cells, and this suppression may be related, in part, to its modulation of NFAT signaling. The emerging role of ICOS in a wide range of immune-related diseases also suggests that it may represent a potential therapeutic target, which could be modulated by cannabinoid compounds.

Key Words: cannabinoid • splenocyte • NFAT • immunomodulation




This article has been cited by other articles:


Home page
 Toxicol SciHome page
H. Lu, R. B. Crawford, C. M. North, B. L. F. Kaplan, and N. E. Kaminski
Establishment of an Immunoglobulin M Antibody-Forming Cell Response Model for Characterizing Immunotoxicity in Primary Human B Cells
Toxicol. Sci., December 1, 2009; 112(2): 363 - 373.
[Abstract] [Full Text] [PDF]